Cargando…

CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes

Previous studies have shown that the CB1 receptor antagonist reverses steatohepatitis and its related features of metabolic syndrome, such as obesity and type 2 diabetes. However, the beneficial effects of CB1 receptor blockade on hepatic steatosis and inflammation have not been investigated indepen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Eugene, Kim, Dae-Hee, Yang, Hyekyung, Lee, Da Hyun, Bae, Soo Han, Park, Cheol-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203369/
https://www.ncbi.nlm.nih.gov/pubmed/30365523
http://dx.doi.org/10.1371/journal.pone.0206152
_version_ 1783365862103711744
author Chang, Eugene
Kim, Dae-Hee
Yang, Hyekyung
Lee, Da Hyun
Bae, Soo Han
Park, Cheol-Young
author_facet Chang, Eugene
Kim, Dae-Hee
Yang, Hyekyung
Lee, Da Hyun
Bae, Soo Han
Park, Cheol-Young
author_sort Chang, Eugene
collection PubMed
description Previous studies have shown that the CB1 receptor antagonist reverses steatohepatitis and its related features of metabolic syndrome, such as obesity and type 2 diabetes. However, the beneficial effects of CB1 receptor blockade on hepatic steatosis and inflammation have not been investigated independently of its effects on body weight and glycemic control. At 32 weeks of age, OLETF rats were administered with rimonabant (10 mg·kg(−1)·day(−1)) by oral gavage for 6 weeks. No significant changes in body weight, OGTT, and serum glucose were observed in spite of rimonabant-decreased food intake. Moreover, there was a significant difference between initial and final body weight, regardless of rimonabant administration, indicating that OLETF rats were severely diabetic rats. Rimonabant administration significantly decreased serum liver enzyme levels such as ALT and AST, hepatic fat accumulation, lipid peroxidation, and cell death as demonstrated by the number of TUNEL-positive cells in severely uncontrolled diabetic OLETF rats. Significant decreases in hepatic gene expression of proinflammatory cytokines (CD11b, F4/80, MCP1, and TNFα), negative inflammatory mediators (SOCS1 and SOCS3), and fibrosis-related proteins (TGFβ, collagen 1, and TIMP1) were found in rimonabant-treated OLETF rats. Six-week administration of rimonabant significantly upregulated mRNA levels of CPT1α and PPARα related to β-oxidation. Moreover, significant increases in Nrf2 gene expression and its downstream genes, NQO1, GSAT, HO-1, and TXNRD1 along with increased AMPK phosphorylation were noted in uncontrolled diabetic rats treated with rimonabant. The observed potent inhibitory effects of CB1 receptor blockade on hepatic fat infiltration and cellular death in severely uncontrolled diabetic rats indicate that CB1 receptor is a possible therapeutic target. Increased Nrf2 and AMPK phosphorylation may play a role in the mechanism of rimonabant action.
format Online
Article
Text
id pubmed-6203369
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62033692018-11-19 CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes Chang, Eugene Kim, Dae-Hee Yang, Hyekyung Lee, Da Hyun Bae, Soo Han Park, Cheol-Young PLoS One Research Article Previous studies have shown that the CB1 receptor antagonist reverses steatohepatitis and its related features of metabolic syndrome, such as obesity and type 2 diabetes. However, the beneficial effects of CB1 receptor blockade on hepatic steatosis and inflammation have not been investigated independently of its effects on body weight and glycemic control. At 32 weeks of age, OLETF rats were administered with rimonabant (10 mg·kg(−1)·day(−1)) by oral gavage for 6 weeks. No significant changes in body weight, OGTT, and serum glucose were observed in spite of rimonabant-decreased food intake. Moreover, there was a significant difference between initial and final body weight, regardless of rimonabant administration, indicating that OLETF rats were severely diabetic rats. Rimonabant administration significantly decreased serum liver enzyme levels such as ALT and AST, hepatic fat accumulation, lipid peroxidation, and cell death as demonstrated by the number of TUNEL-positive cells in severely uncontrolled diabetic OLETF rats. Significant decreases in hepatic gene expression of proinflammatory cytokines (CD11b, F4/80, MCP1, and TNFα), negative inflammatory mediators (SOCS1 and SOCS3), and fibrosis-related proteins (TGFβ, collagen 1, and TIMP1) were found in rimonabant-treated OLETF rats. Six-week administration of rimonabant significantly upregulated mRNA levels of CPT1α and PPARα related to β-oxidation. Moreover, significant increases in Nrf2 gene expression and its downstream genes, NQO1, GSAT, HO-1, and TXNRD1 along with increased AMPK phosphorylation were noted in uncontrolled diabetic rats treated with rimonabant. The observed potent inhibitory effects of CB1 receptor blockade on hepatic fat infiltration and cellular death in severely uncontrolled diabetic rats indicate that CB1 receptor is a possible therapeutic target. Increased Nrf2 and AMPK phosphorylation may play a role in the mechanism of rimonabant action. Public Library of Science 2018-10-26 /pmc/articles/PMC6203369/ /pubmed/30365523 http://dx.doi.org/10.1371/journal.pone.0206152 Text en © 2018 Chang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chang, Eugene
Kim, Dae-Hee
Yang, Hyekyung
Lee, Da Hyun
Bae, Soo Han
Park, Cheol-Young
CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title_full CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title_fullStr CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title_full_unstemmed CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title_short CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
title_sort cb1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases nrf2-ampk pathway in a rat model of severely uncontrolled diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203369/
https://www.ncbi.nlm.nih.gov/pubmed/30365523
http://dx.doi.org/10.1371/journal.pone.0206152
work_keys_str_mv AT changeugene cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes
AT kimdaehee cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes
AT yanghyekyung cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes
AT leedahyun cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes
AT baesoohan cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes
AT parkcheolyoung cb1receptorblockadeameliorateshepaticfatinfiltrationandinflammationandincreasesnrf2ampkpathwayinaratmodelofseverelyuncontrolleddiabetes